Cardio Diagnostics Holdings Unveils AI-Powered Suite to Combat Cardiovascular Disease

Cardio Diagnostics Holdings (NASDAQ: CDIO) is advancing cardiovascular disease prevention with a comprehensive suite of clinical, population health, and biopharma solutions that leverage artificial intelligence, epigenetics, and genetics. The company's offerings aim to address the urgent need for earlier detection and personalized intervention strategies, given that an estimated 80% of cardiovascular disease cases are considered preventable through proactive management of key risk factors.

Cardiovascular disease remains the leading cause of death in the United States, yet many cases could be prevented with earlier detection and tailored interventions. Cardio Diagnostics' platform integrates genetic and epigenetic biomarkers with AI-driven analytics to provide personalized insights from blood-based testing. The company currently offers two clinical solutions: Epi+Gen CHD and PrecisionCHD, which are designed to identify risk earlier and guide personalized intervention strategies.

Research supports the urgent need for more effective tools to identify cardiovascular disease risk earlier and guide personalized care. Cardio Diagnostics' solutions reflect a strategy aimed at addressing cardiovascular disease across multiple stages of care, from prevention to management. This emphasis on prevention aligns with growing recognition that earlier intervention can significantly improve long-term outcomes.

For more information on Cardio Diagnostics and its solutions, visit the company's newsroom at https://ibn.fm/CDIO. The latest news and updates relating to CDIO are available there.

This announcement underscores the potential of AI and genetic insights to transform cardiovascular care. By offering tools that can identify risk earlier and guide personalized strategies, Cardio Diagnostics is positioning itself at the forefront of preventive cardiology. The company's suite of solutions may help reduce the burden of cardiovascular disease by enabling earlier, more targeted interventions.

Forward-looking statements in this article involve risks and uncertainties, as detailed in the company's filings with the SEC. Undue reliance should not be placed on these statements. For full terms of use and disclaimers, refer to http://IBN.fm/Disclaimer.